Objective To investigate the clinical efficacy and safety of azithromycin combined with ceftizoxime and methylprednisolone on the treatment of children with Mycoplasma and lobar pneumonia.Methods A total of 120 children with Mycoplasma and lobar pneumonia from March 2020 to March 2023 were randomly divided into two control group and observation group,with 60 cases per group.Children in the control group were treated with azithromycin and ceftizoxime,and those in the observation group were treated with azithromycin,ceftizoxime plus low-dose methylprednisolone.Clinical symptoms,length of stay,serum C-reactive protein(CRP),lactate dehydrogenase(LDH),erythrocyte sedimentation rate(ESR),arterial blood gas,blood routine,adverse events,clinical efficacy and safety were observed.Results After treatment,clinical symptoms of cough,high fever,lung rales,time of disappearance of lung shadow and length of stay were significantly improved in both groups,which were more pronounced in the observation group than those of control group(P<0.05).Serum levels of CRP,LDH and ESR were significantly improved in both groups,which were more pronounced in the observation group than those of control group(P<0.05).Partial pressure of oxygen(PaO2),partial pressure of carbon dioxide(PaCO2),white blood cell count(WBC),neutrophil count(NEUT)and monocyte count(MONO)were significantly improved in both groups,which were more pronounced in the observation group than those of control group(P<0.05).The total incidence of vomiting,diarrhea and phlebitis was significantly reduced and clinical efficacy was significantly enhanced in both groups,which were more pronounced in the observation group than those of control group(P<0.05).Conclusion The combination of azithromycin,ceftizoxime and low-dose methylprednisolone in the treatment of children with Mycoplasma and lobar pneumonia,presents the advantages of rapid onset,less adverse events,significant efficacy,high safety and effective recovery.
万方数据
维普
